Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin-Reference-Cited by-同舟云学术

Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin

Published:2016-08 Issue: Volume:49 Page:151-153
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Parisi Saverio G.,Loregian Arianna,Andreis Samantha,Nannetti Giulio,Cavinato Silvia,Basso Monica,Scaggiante Renzo,Dal Bello Federico,Messa Lorenzo,Cattelan Anna Maria,Palù Giorgio

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference9 articles.

1. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease;Mandorfer;AIDS,2016

2. Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection;Loregian;J Chromatogr B Analyt Technol Biomed Life Sci,2007

3. Nannetti G, Messa L, Pagni S, Basso M, Palù G, Loregian A. Determination of the hepatitis C virus inhibitor daclatasvir and evaluation of its stability in human plasma by high performance liquid chromatography with UV detection. Manuscript in preparation.

4. Lower ribavirin biodisponibility in patients with HIV–HCV coinfection in comparison with HCV monoinfected patients;Hatu;BMC Infect Dis,2014

5. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+);Leroy;Hepatology,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons;European Journal of Drug Metabolism and Pharmacokinetics;2021-10-08

2. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes;PLOS ONE;2019-05-07

3. Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients;Digestive Diseases and Sciences;2018-01-12

4. UPLC–MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients;Journal of Chromatography B;2018-01

5. Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals;World Journal of Hepatology;2017-12-08